Latest news
StockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel - Genetic Engineering and Biotechnology NewsGenetic Engineering and Biotechnology News · Mon, 03 Aug 2026 00:49:26 GMTFDA AdComm Votes Against Recommending Deramiocel Approval, Tazbentetol Shows Durable Cognitive Benefit in AD, Salanersen's FDA Breakthrough Designation Meaning - NeurologyLiveNeurologyLive · Sat, 01 Aug 2026 23:14:57 GMTCAPR Stock On Track For Worst Week Ever After Regulatory Setback For DMD Therapy - TradingViewTradingView · Fri, 31 Jul 2026 17:42:39 GMTDuchenne Therapy Has Aug. 22 FDA Action Target After Panel Vote - Stock TitanStock Titan · Thu, 30 Jul 2026 13:30:00 GMTFDA Advisory Panel Votes Against Approval of Deramiocel for DMD - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Thu, 30 Jul 2026 07:00:00 GMTFDA Advisory Committee Votes Against Deramiocel for DMD Cardiomyopathy - NeurologyLiveNeurologyLive · Wed, 29 Jul 2026 07:00:00 GMTFDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute - Fierce BiotechFierce Biotech · Wed, 29 Jul 2026 07:00:00 GMTFDA expert panel recommends against approval of Capricor’s Duchenne drug - STATSTAT · Wed, 29 Jul 2026 07:00:00 GMT